IL251477A0 - Anti-ang2 antibodies and methods of use - Google Patents

Anti-ang2 antibodies and methods of use

Info

Publication number
IL251477A0
IL251477A0 IL251477A IL25147717A IL251477A0 IL 251477 A0 IL251477 A0 IL 251477A0 IL 251477 A IL251477 A IL 251477A IL 25147717 A IL25147717 A IL 25147717A IL 251477 A0 IL251477 A0 IL 251477A0
Authority
IL
Israel
Prior art keywords
methods
ang2 antibodies
ang2
antibodies
Prior art date
Application number
IL251477A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL251477A0 publication Critical patent/IL251477A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL251477A 2014-11-10 2017-03-30 Anti-ang2 antibodies and methods of use IL251477A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192524 2014-11-10
PCT/EP2015/075876 WO2016075035A1 (en) 2014-11-10 2015-11-06 Anti-ang2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
IL251477A0 true IL251477A0 (en) 2017-05-29

Family

ID=51868115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251477A IL251477A0 (en) 2014-11-10 2017-03-30 Anti-ang2 antibodies and methods of use

Country Status (14)

Country Link
US (1) US10538585B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218398A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017534644A (cg-RX-API-DMAC7.html)
KR (1) KR20170082594A (cg-RX-API-DMAC7.html)
CN (1) CN107001456A (cg-RX-API-DMAC7.html)
AR (1) AR102595A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015345321A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017009790A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963606A1 (cg-RX-API-DMAC7.html)
IL (1) IL251477A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017005642A (cg-RX-API-DMAC7.html)
SG (1) SG11201703458UA (cg-RX-API-DMAC7.html)
TW (1) TW201630935A (cg-RX-API-DMAC7.html)
WO (1) WO2016075035A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
JP7074859B2 (ja) * 2017-12-22 2022-05-24 エフ．ホフマン－ラ ロシュ アーゲー 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
JP2023530187A (ja) 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
US20230312698A1 (en) * 2020-08-07 2023-10-05 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
CA3192239A1 (en) * 2020-08-19 2022-02-24 Pharmabcine Inc. Modified antibody and method for manufacturing same
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AU2003208946A1 (en) 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2509136C (en) 2003-01-24 2013-10-29 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2727171A1 (en) 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
MX2013001267A (es) 2010-08-13 2013-04-10 Genentech Inc ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
CA2830254C (en) * 2011-03-16 2019-09-10 Amgen Inc. Fc variants
JP6069312B2 (ja) * 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
US9695233B2 (en) * 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
CN104661678A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合
KR20150060686A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF 제제를 포함하는 약제학적 조합물
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
EP2917237A1 (en) 2012-11-09 2015-09-16 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PE20160753A1 (es) * 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
RU2727639C2 (ru) * 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
JP6946184B2 (ja) 2014-11-10 2021-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｐｄｇｆ−ｂ抗体及び使用法
KR20170080584A (ko) * 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
WO2016075034A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
US20190004048A1 (en) * 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
US11198726B2 (en) * 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy

Also Published As

Publication number Publication date
US20170247441A1 (en) 2017-08-31
AU2015345321A1 (en) 2017-04-20
KR20170082594A (ko) 2017-07-14
AR102595A1 (es) 2017-03-08
CN107001456A (zh) 2017-08-01
JP2021050229A (ja) 2021-04-01
TW201630935A (zh) 2016-09-01
JP2017534644A (ja) 2017-11-24
BR112017009790A2 (pt) 2017-12-19
SG11201703458UA (en) 2017-05-30
WO2016075035A1 (en) 2016-05-19
MX2017005642A (es) 2017-07-24
US10538585B2 (en) 2020-01-21
EP3218398A1 (en) 2017-09-20
CA2963606A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL279606A (en) Anti-TREM2 antibodies and methods of using them
IL251868B (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
IL257636A (en) Anti-tigit antibodies and methods of use
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
EP3116911B8 (en) Anti-mcam antibodies and associated methods of use
IL248399A0 (en) New anti-43rnf antibodies and methods of use
IL247754A0 (en) Antibodies against mcam and related methods of use
IL251477A0 (en) Anti-ang2 antibodies and methods of use
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use